Completed

Octreotide for Palliation of Inoperable Bowel Obstruction: A Phase II Study

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

octreotide acetate

Drug
Who is being recruted

Urogenital Diseases+45

+ Genital Diseases

+ Adnexal Diseases

Over 18 Years
See all eligibility criteria
How is the trial designed

Supportive Care Study

Phase 2
Interventional
Study Start: October 1999
See protocol details

Summary

Principal SponsorNorthwestern University
Last updated: June 6, 2012
Sourced from a government-validated database.Claim as a partner

Study start date: October 1, 1999

Actual date on which the first participant was enrolled.

OBJECTIVES: Determine the effectiveness of octreotide in the palliation of bowel obstruction secondary to cancer. Characterize the dose and tolerability of octreotide in this patient population. OUTLINE: Patients receive octreotide subcutaneously or IV over 24 hours on days 2-5. Patients who respond well to study may continue octreotide for palliative effects. PROJECTED ACCRUAL: A total of 9-25 patients will be accrued for this study over 9 months.

NCT00004895
Principal SponsorNorthwestern University
Last updated: June 6, 2012
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Supportive Care Study

These studies explore ways to improve comfort and daily life for people living with a condition. They may focus on easing symptoms, reducing treatment side effects, or supporting overall well-being.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Urogenital DiseasesGenital DiseasesAdnexal DiseasesBile Duct DiseasesBiliary Tract DiseasesBiliary Tract NeoplasmsCarcinomaColonic DiseasesDigestive System DiseasesDigestive System NeoplasmsEndocrine System DiseasesEndocrine Gland NeoplasmsFemale Urogenital Diseases and Pregnancy ComplicationsGastrointestinal DiseasesGastrointestinal NeoplasmsGenital Diseases, FemaleGenital Neoplasms, FemaleGonadal DisordersIntestinal DiseasesIntestinal NeoplasmsNeoplasmsNeoplasms by Histologic TypeNeoplasms by SiteNeoplasms, Connective TissueNeoplasms, Glandular and EpithelialOvarian DiseasesPancreatic DiseasesRectal DiseasesSigns and SymptomsSigns and Symptoms, DigestiveStomach DiseasesPathological Conditions, Signs and SymptomsUrogenital NeoplasmsNeoplasms, Connective and Soft TissueFemale Urogenital DiseasesCarcinoma, Ovarian EpithelialBile Duct NeoplasmsColonic NeoplasmsConstipationIntestinal ObstructionNauseaOvarian NeoplasmsPancreatic NeoplasmsRectal NeoplasmsStomach NeoplasmsVomitingColorectal NeoplasmsGastrointestinal Stromal Tumors

Criteria

DISEASE CHARACTERISTICS: Inoperable bowel obstruction secondary to cancer OR Metastatic or primary abdominal cancer Patient presents with vomiting Percutaneous gastrostomy tube allowed PATIENT CHARACTERISTICS: Age: Over 18 Performance status: ECOG 0-4 Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: No documented hypersensitivity to octreotide Not pregnant or nursing PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Prior chemotherapy allowed Endocrine therapy: Concurrent steroids allowed Radiotherapy: Prior radiotherapy allowed Surgery: Not specified

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Robert H. Lurie Comprehensive Cancer Center, Northwestern University

Chicago, United StatesOpen Robert H. Lurie Comprehensive Cancer Center, Northwestern University in Google Maps
CompletedOne Study Center